The FDA approved Fycompa (perampanel) tablets as an adjunctive therapy for adult patients with epilepsy for the treatment of partial-onset seizures with or without secondarily generalized seizures.
The FDA approved Gilead Sciences, Inc.'s Truvada (emtricitabine 200 mg/tenofovir disproxil fumarate 300 mg) in combination with safer sex practices for pre-exposure prophylaxis.
The FDA approved Erivedge (vismodegib) for the treatment of basal cell carcinoma in adult patients.
The FDA has expanded the indication of Merck's Isentress (raltegravir) to include pediatric patients.
The FDA has approved Vertex Pharmaceuticals, Inc's Kalydeco (ivacaftor) tablets for the treatment of cystic fibrosis in patients who are 6 years and older.
Bristol-Myers Squibb's Sprycel (dasatinib) tablets were approved by the FDA for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA approved Lundbeck, Inc's Onfi (clobazam) as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients that are 2 years and older.
Gilead Sciences, Inc's Complera received approval from the FDA for use as a complete regimen for the treatment of HIV-1 infection in treatment-naÃ¯ve adults.
The FDA approved a subcutaneous formulation of Bristol-Myers Squibb's Orencia (abatacept) for the treatment of moderately to severely active rheumatoid arthritis in adults.
The FDA approved Genentech's Zelboraf (vermurafenib) for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation.